Rexgenero receives Scientific Advice letter from the Medicines & Healthcare products Regulatory Agency (MHRA)


Rexgenero receives scientific advice from the MHRA (the UK pharmaceutical regulator) regarding quality and clinical aspects of Rexgenero planned phase III study with REX-001 in critical limb ischemia following a meeting with MHRA on 17th September 2015. The MHRA confirmed that the proposed multi-centre, randomized placebo-controlled design as well as the dose is acceptable.

innovative cell therapies
Contact us